Genomic damage and circulating AGE levels in patients undergoing daily versus standard haemodialysis

• Published in: Nephrology, dialysis, transplantation dialysis, transplantation, 2005-09, Vol.20 (9), p.1936-1943
• Main Authors: Fragedaki, Evangelia, Nebel, Michael, Schupp, Nicole, Sebekova, Katarina, Völkel, Wolfgang, Klassen, André, Pischetsrieder, Monika, Frischmann, Matthias, Niwa, Toshimitsu, Vienken, Jörg, Heidland, August, Stopper, Helga
• Format: Article
• Language: English
• Subjects: Adult; advanced glycation endproducts; Aged; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Arginine - analogs & derivatives; Arginine - blood; Biological and medical sciences; C-Reactive Protein - metabolism; Cross-Sectional Studies; daily haemodialysis; DNA Damage; Emergency and intensive care: renal failure. Dialysis management; Female; Glomerulonephritis; Glycation End Products, Advanced - blood; Humans; Imidazoles - blood; Intensive care medicine; Interleukin-6 - blood; Kidney Failure, Chronic - blood; Kidney Failure, Chronic - therapy; Lysine - analogs & derivatives; Lysine - blood; Male; Medical sciences; micronuclei frequency; Micronucleus Tests; Middle Aged; Nephrology. Urinary tract diseases; Nephropathies. Renovascular diseases. Renal failure; oxidative stress; Reference Values; Renal Dialysis - adverse effects; Renal Dialysis - methods; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Surgery of the urinary system
• ISSN: 0931-0509; 1460-2385
• DOI: 10.1093/ndt/gfh898

Background. Patients with end-stage renal failure, whether on conservative or haemodialysis therapy, have a high incidence of DNA damage. It is not known if improved control of the uraemic state by daily haemodialysis (DHD) reduces DNA lesions. Methods. DNA damage in peripheral blood lymphocytes (PBLs) was evaluated in a cross-sectional study of 13 patients on DHD (2–3 h, 6 times/week), 12 patients on standard haemodialysis (SHD) therapy (4–5 h, 3 times/week) and 12 healthy age-matched volunteer controls. The biomarker of DNA damage used was micronucleus frequency. The assessed plasma parameters of microinflammation and oxidative stress were C-reactive protein (CRP), interleukin-6 (IL-6), neopterin, advanced oxidation protein products (AOPP), and homocysteine. We also measured plasma concentrations of the circulating advanced glycation end products (AGEs) MGI (methylglyoxal-derived imidazolinone), CML (carboxymethyllysine), imidazolone A (3-deoxyglucosone-derived imidazolinone) and AGE-associated fluorescence. Results. Compared to SHD, DHD was associated with significantly lower DNA damage, approaching the normal range. Micronuclei (MN) frequency averaged 29.1 MN±5.9/1000 binucleated (BN) cells in the SHD group, which is significantly elevated (P